Radiosensitivity enhancement of bismuth-based nanoparticles in radiotherapy: A systematic review and meta-analysis
Abstract
Introduction: Nano-biomaterials facilitate targeted drug delivery and serve as radio-sensitizers, reducing therapeutic doses and side effects while enhancing efficacy. This meta-analysis aims to investigate the impact of bismuth-based nanoparticles on enhancing radiosensitivity, specifically by evaluating the dose enhancement factor (DEF) in radiotherapy.
Materials and methods: This systematic review and meta-analysis evaluated the radiosensitizing effect of bismuth-based nanoparticles. PubMed, Web of Science, and Scopus were searched for eligible studies. The cumulative dose enhancement factor (DEF) was assessed, and subgroup and sensitivity analyses were performed to investigate the effect of nanoparticle size and concentration on radiosensitization.
Results: The average dose enhancement factor (DEF) for bismuth concentrations 0.05). This indicates that bismuth concentrations above 50 are not more effective against tumor cells. In contrast, the mean DEF for tumor sizes 10 was 1.21 and 1.51, respectively (P = 0.02). Nanoparticle size significantly influenced radiosensitization, with particles larger than 10 nm producing higher DEF values compared with smaller particles. In contrast, increasing nanoparticle concentration did not lead to a proportional increase in DEF, suggesting possible biological saturation or toxicity effects.
Conclusions: These findings suggest increasing nanoparticle concentration above 50 µg/mL did not further enhance the radiosensitizing effect…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.